{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atopic+Hypersensitivity&page=2", "query": { "condition": "Atopic Hypersensitivity", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Atopic+Hypersensitivity&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T08:58:03.588Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07352566", "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "In situ cutaneous microdevice", "type": "DEVICE" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Calcipotriene", "type": "DRUG" }, { "name": "Tapinarof", "type": "DRUG" }, { "name": "Crisaborole", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Baractinib", "type": "DRUG" }, { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-08-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352566" }, { "nct_id": "NCT04718870", "title": "Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Dermatitis Atopic" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 41, "start_date": "2021-02-19", "completion_date": "2022-11-30", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 2, "location_summary": "Los Angeles, California • Denver, Colorado", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04718870" }, { "nct_id": "NCT01859988", "title": "Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2013-05", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-08-28", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859988" }, { "nct_id": "NCT02647086", "title": "Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Metoprolol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2015-12", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-08-22", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Berlin", "state": "New Jersey" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02647086" }, { "nct_id": "NCT01494142", "title": "Registry for the Atopic Dermatitis Research Network", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atopic Dermatitis", "Eczema Herpeticum" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Months", "maximum_age": "80 Years", "sex": "ALL", "summary": "8 Months to 80 Years" }, "enrollment_count": 3387, "start_date": "2011-08", "completion_date": "2018-02-07", "has_results": false, "last_update_posted_date": "2018-09-19", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 9, "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01494142" }, { "nct_id": "NCT02950922", "title": "Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "RVT-501 0.2% ointment", "type": "DRUG" }, { "name": "RVT-501 0.5% ointment", "type": "DRUG" }, { "name": "Vehicle ointment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dermavant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "12 Years to 70 Years" }, "enrollment_count": 157, "start_date": "2016-11", "completion_date": "2017-07-03", "has_results": false, "last_update_posted_date": "2018-08-06", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 16, "location_summary": "Fremont, California • Los Angeles, California • San Diego, California + 10 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02950922" }, { "nct_id": "NCT00407069", "title": "Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atopic Dermatitis" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 286, "start_date": "2005-06", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2016-10-18", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407069" }, { "nct_id": "NCT00546000", "title": "Cutivate Lotion HPA Axis Pediatric Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Fluticasone propionate 0.05% lotion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fougera Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "12 Months", "sex": "ALL", "summary": "3 Months to 12 Months" }, "enrollment_count": 56, "start_date": "2007-07", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 10, "location_summary": "Poway, California • San Diego, California • Miami, Florida + 7 more", "locations": [ { "city": "Poway", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Eagan", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546000" }, { "nct_id": "NCT05602207", "title": "Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Abrocitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovaderm Research Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-11-25", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-03-28", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Miami Lakes, Florida + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Quincy", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05602207" }, { "nct_id": "NCT03745638", "title": "Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib Cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 631, "start_date": "2018-12-20", "completion_date": "2020-12-01", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-09-22T08:58:03.588Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745638" } ] }